Epstein-Barr Virus-associated carcinoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:289651
Who is this for?
Show terms as
2Active trials15Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Epstein-Barr Virus-associated carcinoma (also called EBV-associated carcinoma) is a group of cancers that develop in connection with infection by the Epstein-Barr virus (EBV). EBV is a very common virus — most people are infected at some point in their lives — but in rare cases, the virus can contribute to the development of certain cancers. The most well-known types of EBV-associated carcinomas include nasopharyngeal carcinoma (cancer of the area behind the nose and above the throat) and certain types of stomach (gastric) cancer. In these cancers, the virus inserts its genetic material into the cells and produces proteins that help the cancer cells grow and avoid the immune system. Symptoms depend on where the cancer develops. Nasopharyngeal carcinoma may cause a lump in the neck, hearing loss, nasal congestion, nosebleeds, or headaches. EBV-associated gastric cancer may cause stomach pain, nausea, weight loss, and difficulty swallowing. Diagnosis typically involves biopsy of the tumor along with testing for the presence of EBV within the cancer cells. Treatment usually includes a combination of surgery, radiation therapy, and chemotherapy, depending on the cancer type and stage. Immunotherapy has become an increasingly important treatment option, particularly checkpoint inhibitors that help the immune system recognize and attack cancer cells. Because EBV-positive cancers often have distinct biological features, researchers are actively studying targeted therapies and virus-specific treatments. Prognosis varies widely depending on the specific cancer type, stage at diagnosis, and response to treatment.

Also known as:

Key symptoms:

Lump or swelling in the neckPersistent nasal congestion or stuffinessNosebleedsHearing loss or ringing in the earsHeadachesDifficulty swallowingUnexplained weight lossStomach pain or discomfortNausea or vomitingLoss of appetiteFatigue and tirednessBlood in the stool (for gastric type)Feeling of fullness after eating small amountsDouble vision or facial numbness

Inheritance

Multifactorial

Caused by a mix of several genes and environmental factors

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

FDA & Trial Timeline

4 events
Jun 2026Pembrolizumab + MRGOO3 as Neoadjuvant in NPC

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — PHASE2

TrialNOT YET RECRUITING
Mar 2025Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma

University of California, San Francisco — NA

TrialRECRUITING
Jan 2025KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial

Kousai Bio Co., Ltd. — EARLY_PHASE1

TrialNOT YET RECRUITING
Jan 2022Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

Stanford University — PHASE2

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Epstein-Barr Virus-associated carcinoma.

2 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

2 recruitingView all trials with filters →
Phase 21 trial
Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Phase 2
Active
PI: A. Dimitrios Colevas (Stanford Universiy) · Sites: Stanford, California · Age: 1899 yrs
N/A1 trial
Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
N/A
Actively Recruiting
PI: Sue Yom, MD, PhD (University of California, San Francisco) · Sites: San Francisco, California · Age: 1899 yrs

Specialists

15 foundView all specialists →
AM
A. Dimitrios Colevas, MD
Specialist
PI on 3 active trials1 Epstein-Barr Virus-associated carcinoma publication
AC
A. Dimitrios Colevas
Specialist
PI on 1 active trial1 Epstein-Barr Virus-associated carcinoma publication
SP
Sue Yom, MD, PhD
SAN FRANCISCO, CA
Specialist
PI on 1 active trial
JY
Jiren Yu
Specialist
PI on 3 active trials385 Epstein-Barr Virus-associated carcinoma publications
PM
Paul Martin
Specialist
PI on 3 active trials73 Epstein-Barr Virus-associated carcinoma publications
SM
Shivaani Kummar, MD
PORTLAND, OR
Specialist
PI on 5 active trials
JS
John Sarantopoulos
SAN ANTONIO, TX
Specialist
PI on 1 active trial2 Epstein-Barr Virus-associated carcinoma publications
SM
Scot C. Remick, MD
SCARBOROUGH, ME
Specialist
PI on 9 active trials
JP
Joseph Bubalo, PharmD
PORTLAND, OR
Specialist
PI on 2 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Epstein-Barr Virus-associated carcinoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Epstein-Barr Virus-associated carcinomaForum →

No community posts yet. Be the first to share your experience with Epstein-Barr Virus-associated carcinoma.

Start the conversation →

Latest news about Epstein-Barr Virus-associated carcinoma

Disease timeline:

New recruiting trial: Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City

A new clinical trial is recruiting patients for Epstein-Barr Virus-associated carcinoma

New recruiting trial: Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma

A new clinical trial is recruiting patients for Epstein-Barr Virus-associated carcinoma

New recruiting trial: Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

A new clinical trial is recruiting patients for Epstein-Barr Virus-associated carcinoma

New recruiting trial: Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

A new clinical trial is recruiting patients for Epstein-Barr Virus-associated carcinoma

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What specific type of EBV-associated carcinoma do I have, and what stage is it?,What treatment options are available for my specific situation, and what are the expected benefits and side effects?,Am I eligible for immunotherapy or any clinical trials targeting EBV-related cancers?,How will treatment affect my ability to eat, speak, and carry out daily activities?,What follow-up schedule will I need after treatment, and how will you monitor for recurrence?,Should my family members be screened, especially if we come from a high-risk population?,What supportive care services are available to help me manage side effects and maintain quality of life?

Common questions about Epstein-Barr Virus-associated carcinoma

What is Epstein-Barr Virus-associated carcinoma?

Epstein-Barr Virus-associated carcinoma (also called EBV-associated carcinoma) is a group of cancers that develop in connection with infection by the Epstein-Barr virus (EBV). EBV is a very common virus — most people are infected at some point in their lives — but in rare cases, the virus can contribute to the development of certain cancers. The most well-known types of EBV-associated carcinomas include nasopharyngeal carcinoma (cancer of the area behind the nose and above the throat) and certain types of stomach (gastric) cancer. In these cancers, the virus inserts its genetic material into t

How is Epstein-Barr Virus-associated carcinoma inherited?

Epstein-Barr Virus-associated carcinoma follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Epstein-Barr Virus-associated carcinoma typically begin?

Typical onset of Epstein-Barr Virus-associated carcinoma is adult. Age of onset can vary across affected individuals.

Are there clinical trials for Epstein-Barr Virus-associated carcinoma?

Yes — 2 recruiting clinical trials are currently listed for Epstein-Barr Virus-associated carcinoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Epstein-Barr Virus-associated carcinoma?

15 specialists and care centers treating Epstein-Barr Virus-associated carcinoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.